Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma

Reuters11-13

Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma

Delcath Systems Inc. has announced the publication of a retrospective analysis conducted by researchers at the University of Tubingen, Germany, evaluating the outcomes of liver-directed therapies in patients with metastatic uveal melanoma (mUM) and liver metastases. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of chemosaturation therapy-also known as percutaneous hepatic perfusion (PHP)-using Delcath's CHEMOSAT® Hepatic Delivery System, which utilizes the same technology as the FDA-approved HEPZATO KIT™. Results from the analysis indicate that PHP, when used as a first-line liver-directed therapy, achieved a 100% disease control rate and was associated with improved melanoma-specific survival compared to systemic therapies. Previous related data from this research group were presented at the European Association of Dermato-Oncology (EADO) Congress in April 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113964803) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583562593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583562593","market":"nz","top_or_hot":-1,"title":"Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> Inc. has announced the publication of a retrospective analysis conducted by researchers at the University of Tubingen, Germany, evaluating the outcomes of liver-directed therapies in patients with metastatic uveal melanoma (mUM) and liver metastases. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of chemosaturation therapy-also known as percutaneous hepatic perfusion (PHP)-using Delcath's CHEMOSAT® Hepatic Delivery System, which utilizes the same technology as the FDA-approved HEPZATO KIT™. Results from the analysis indicate that PHP, when used as a first-line liver-directed therapy, achieved a 100% disease control rate and was associated with improved melanoma-specific survival compared to systemic therapies. Previous related data from this research group were presented at the European Association of Dermato-Oncology (EADO) Congress in April 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113964803) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> Inc. has announced the publication of a retrospective analysis conducted by researchers at the University of Tubingen, Germany, evaluating the outcomes of liver-directed therapies in patients with metastatic uveal melanoma (mUM) and liver metastases. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of chemosaturation therapy-also known as percutaneous hepatic perfusion (PHP)-using Delcath's CHEMOSAT® Hepatic Delivery System, which utilizes the same technology as the FDA-approved HEPZATO KIT™. Results from the analysis indicate that PHP, when used as a first-line liver-directed therapy, achieved a 100% disease control rate and was associated with improved melanoma-specific survival compared to systemic therapies. Previous related data from this research group were presented at the European Association of Dermato-Oncology (EADO) Congress in April 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113964803) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLqdjPj:1","article_id":"2583562593","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583562593","pubTimestamp":1763040663,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Delcath Systems Inc. has announced the publication of a retrospective analysis conducted by researchers at the University of Tubingen, Germany, evaluating the outcomes of liver-directed therapies in patients with metastatic uveal melanoma  and liver metastases. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of chemosaturation therapy-also known as percutaneous hepatic perfusion -using Delcath's CHEMOSAT Hepatic Delivery System, which utilizes the same technology as the FDA-approved HEPZATO KIT. Results from the analysis indicate that PHP, when used as a first-line liver-directed therapy, achieved a 100% disease control rate and was associated with improved melanoma-specific survival compared to systemic therapies. Previous related data from this research group were presented at the European Association of Dermato-Oncology  Congress in April 2025.Disclaimer: This news brief was created by Public Technologies  using generative ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","DCTH":"迪卡斯"},"translate_title":"Delcath研究显示早期肝脏导向PHP治疗可提高转移性葡萄膜黑色素瘤的生存率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCTH":0.9},"content_text":"Delcath Study Shows Early Liver-Directed PHP Therapy Improves Survival in Metastatic Uveal Melanoma\n    \n\nDelcath Systems Inc. has announced the publication of a retrospective analysis conducted by researchers at the University of Tubingen, Germany, evaluating the outcomes of liver-directed therapies in patients with metastatic uveal melanoma (mUM) and liver metastases. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of chemosaturation therapy-also known as percutaneous hepatic perfusion (PHP)-using Delcath's CHEMOSAT® Hepatic Delivery System, which utilizes the same technology as the FDA-approved HEPZATO KIT™. Results from the analysis indicate that PHP, when used as a first-line liver-directed therapy, achieved a 100% disease control rate and was associated with improved melanoma-specific survival compared to systemic therapies. Previous related data from this research group were presented at the European Association of Dermato-Oncology (EADO) Congress in April 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113964803) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583562593","isCrawlerRequest":true}